Literature DB >> 26863873

Cancer clinical trial enrollment of diverse and underserved patients within an urban safety net hospital.

Naomi Y Ko1, Julie L Fu2, Sarah C Lane3, Kathy Finn4, Sandy Allten4, Nectaria Vassilakis4, Lisa Stober4, Lisa Kachnic5, Tracy A Battaglia3.   

Abstract

BACKGROUND: Enrollment rates onto cancer clinical trials are low and reflect a small subset of the population of which even fewer participants come from populations of racial or ethnic diversity or low socioeconomic status. There is a need to increase enrollment onto cancer clinical trials with a focus on recruitment of a diverse, underrepresented patient population.
OBJECTIVE: To use the electronic medical record (EMR) to understand the eligibility and enrollment rates for all available cancer trials in the ambulatory care setting at an urban safety net hospital to identify specific strategies for enhanced accrual onto cancer clinical trials of diverse and underserved patients.
METHODS: A clinical trial screening note was created for the EMR by the clinical trials office at an urban safety net hospital. 847 cancer clinical trial screening notes were extracted from the EMR between January 1, 2010 and December 31, 2010. During that time, 99 cancer trials were registered for accrual, including clinical treatment, survey, data repository, imaging, and symptom management trials. Data on eligibility, enrollment status, and relationship to sociodemographic status were compared. LIMITATIONS: This is a single-institution and retrospective study.
CONCLUSIONS: The findings demonstrate that a formal process of tracking cancer clinical trial screens using an EMR can document baseline rates of institution-specific accrual patterns and identify targeted strategies for increasing cancer clinical trial enrollment among a vulnerable patient population. Offering nontreatment trials may be an important and strategic method of engaging this vulnerable population in clinical research. ©2015 Frontline Medical Communications.

Entities:  

Keywords:  cancer disparities; clinical informatics; clinical trials; eligibility determination; research patient recruitment

Year:  2015        PMID: 26863873     DOI: 10.12788/jcso.0181

Source DB:  PubMed          Journal:  J Community Support Oncol        ISSN: 2330-7749


  5 in total

1.  Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Authors:  Herbert H Pang; Xiaofei Wang; Thomas E Stinchcombe; Melisa L Wong; Perry Cheng; Apar Kishor Ganti; Daniel J Sargent; Ying Zhang; Chen Hu; Sumithra J Mandrekar; Mary W Redman; Judith B Manola; Richard L Schilsky; Harvey J Cohen; Jeffrey D Bradley; Alex A Adjei; David Gandara; Suresh S Ramalingam; Everett E Vokes
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

2.  White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival among Adults Aged 85 Years and Older in the United States.

Authors:  Jessica L Krok-Schoen; James L Fisher; Ryan D Baltic; Electra D Paskett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-15       Impact factor: 4.254

3.  African American Cancer Survivors' Perspectives on Cancer Clinical Trial Participation in a Safety-Net Hospital: Considering the Role of the Social Determinants of Health.

Authors:  N D Hernandez; R Durant; N Lisovicz; C Nweke; C Belizaire; D Cooper; F Soiro; D Rivers; S Sodeke; B M Rivers
Journal:  J Cancer Educ       Date:  2021-03-16       Impact factor: 1.771

4.  Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey.

Authors:  Elise D Cook; Katherine A Yeager; Reena S Cecchini; Jaskaran Boparai; Carol L Brown; Martha Duncan; Walter M Cronin; Electra D Paskett
Journal:  Contemp Clin Trials Commun       Date:  2018-03-09

5.  Novel semi-automated algorithm for high-throughput quantification of adipocyte size in breast adipose tissue, with applications for breast cancer microenvironment.

Authors:  Frank L Lombardi; Naser Jafari; Kimberly A Bertrand; Lauren J Oshry; Michael R Cassidy; Naomi Y Ko; Gerald V Denis
Journal:  Adipocyte       Date:  2020-12       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.